Document Detail

Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis.
MedLine Citation:
PMID:  17921331     Owner:  NLM     Status:  MEDLINE    
This study was designed to determine the effect of inhibitors of cyclooxygenase (COX)-1, COX-2, and the nonselective COX inhibitor naproxen on coronary vasoactivity and thrombogenicity under baseline and lipopolysaccharide (LPS)-induced inflammatory conditions. We hypothesize that endothelial COX-1 is the primary COX isoform in the canine normal coronary artery, which mediates arachidonic acid (AA)-induced vasodilatation. However, COX-2 can be induced and overexpressed by inflammatory mediators and becomes the major local COX isoform responsible for the production of antithrombotic prostaglandins during systemic inflammation. The interventions included the selective COX-1 inhibitor SC-560 (0.3 mg/kg iv), the selective COX-2 inhibitor nimesulide (5 mg/kg iv), or the nonselective COX inhibitor naproxen (3 mg/kg iv). The selective prostacyclin (IP) receptor antagonist RO-3244794 (RO) was used as an investigational tool to delineate the role of prostacyclin (PGI(2)) in modulating vascular reactivity. AA-induced vasodilatation of the left circumflex coronary artery was suppressed to a similar extent by each of the COX inhibitors and RO. The data suggest that AA-induced vasodilatation in the normal coronary artery is mediated by a single COX isoform, the constitutive endothelial COX-1, which is reported to be susceptible to COX-2 inhibitors. The effect of the COX inhibitors on thrombus formation was evaluated in a model of carotid artery thrombosis secondary to electrolytic-induced vessel wall injury. Pretreatment with LPS (0.5 mg/kg iv) induced a systemic inflammatory response and prolonged the time-to-occlusive thrombus formation, which was reduced in the LPS-treated animals by the administration of nimesulide. In contrast, neither SC-560 nor naproxen influenced the time to thrombosis in the animals pretreated with LPS. The data are of significance in view of reported adverse cardiovascular events observed in clinical trials involving the use of selective COX-2 inhibitors, thereby suggesting that the endothelial constitutive COX-1 and the inducible vascular COX-2 serve important functions in maintaining vascular homeostasis.
Ting-Ting Hong; Jinbao Huang; Terrance D Barrett; Benedict R Lucchesi
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-10-05
Journal Detail:
Title:  American journal of physiology. Heart and circulatory physiology     Volume:  294     ISSN:  0363-6135     ISO Abbreviation:  Am. J. Physiol. Heart Circ. Physiol.     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2008-01-14     Completed Date:  2008-02-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100901228     Medline TA:  Am J Physiol Heart Circ Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  H145-55     Citation Subset:  IM    
Department of Pharmacology, University of Michigan Medical School, 1150 W. Medical Center Drive, Ann Arbor, MI 48109-0632, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetylcholine / pharmacology
Arachidonic Acid / metabolism
Benzofurans / pharmacology
Carotid Arteries / surgery
Coronary Circulation / drug effects*
Coronary Vessels / drug effects*,  enzymology,  physiopathology
Cyclooxygenase 1 / metabolism*
Cyclooxygenase 2 / metabolism*
Cyclooxygenase 2 Inhibitors / pharmacology
Cyclooxygenase Inhibitors / adverse effects,  pharmacology*
Disease Models, Animal
Dose-Response Relationship, Drug
Electric Stimulation
Epoprostenol / metabolism
Inflammation / blood,  chemically induced,  enzymology*,  physiopathology
Naproxen / pharmacology
Platelet Aggregation / drug effects
Propionic Acids / pharmacology
Pyrazoles / pharmacology
Receptors, Epoprostenol / antagonists & inhibitors,  metabolism
Sulfonamides / pharmacology
Thrombosis / blood,  enzymology*,  etiology,  physiopathology
Time Factors
Vasodilation / drug effects*
Vasodilator Agents / pharmacology
Reg. No./Substance:
0/Benzofurans; 0/Cyclooxygenase 2 Inhibitors; 0/Cyclooxygenase Inhibitors; 0/Lipopolysaccharides; 0/Propionic Acids; 0/Pyrazoles; 0/RO3244794; 0/Receptors, Epoprostenol; 0/SC 560; 0/Sulfonamides; 0/Vasodilator Agents; 22204-53-1/Naproxen; 35121-78-9/Epoprostenol; 506-32-1/Arachidonic Acid; 51-84-3/Acetylcholine; 51803-78-2/nimesulide; EC 1; EC 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Increased metaboreflex activity is related to exercise intolerance in heart transplant patients.
Next Document:  Inducible and myocyte-specific inhibition of PKCalpha enhances cardiac contractility and protects ag...